Defymed Receives Support from JDRF to Fight Type 1 Diabetes

Posted on July 12, 2016

Strasbourg, July 12, 2016. Defymed today announced a partnership with JDRF, the leading global organization funding type 1 diabetes (T1D) research. This new investment gives Defymed the opportunity to advance its pre-clinical studies in order to demonstrate the MAILPAN® immunoprotection properties, safety and function. This is an essential step before beginning the clinical trials on humans.
Read full post »

Defymed at RESI conference – Boston

Posted on July 11, 2016

13 Septembre 2016: Defymed’s CEO, Dr. Séverine SIGRIST will be present at the RESI conference 2016 in Boston- USA. It will be a great opportunity to meet you and discuss Defymed’s innovations and business. Contact us For more info on RESI

Defymed at BIOPHARM AMERICA– Boston

Posted on July 11, 2016

13-15 Septembre 2016: Defymed will be present at the BIOPHARM AMERICA exhibition 2016 in Boston- USA. That event will be a great opportunity to discuss our latest news and to Partner together. We are looking forward to meeting you! Contact us For more info on Biopharm